Ann: Kazia paxalisib Phase II interim data, page-18

Great post Rikki

There have been a lot of negative posts today from usually positive people on the various threads today.

Nobody appears to think the interim data was poor so that just leaves the trading halt

I agree with Rich & Poor -mostly
"In requesting the trading halt, the Company provides the following information
:(a)the trading halt is requested in respect of finalising an announcement on a financing transaction;

"Raising 7.2mil @40 cents does not make sense!
IMO finalising a deal regarding Paxalisib is a more likely outcome.

Clearly a raise at 60cents would be better than 40cents -but its all about how funds will be directed

a. To assist in finalising a Paxalisib deal ( positive outcome for shareholders )
b. To assist in financing start up costs of Agile Trial ( positive outcome for shareholders )
c. To simply fund them to the presentation of final Data 1H2021 (positive outcome for shareholders )


This is only a 10% dilution and who can say access to funds will be easier in the coming months. I for one will participate given the opportunity

If not well done to James & Board for taking the opportunity to fund the company in these uncertain times.